Company intelligence / Profile preview

AptamiR Therapeutics

Austin, Texas, United Statesaptamir.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Proofs of efficacy for first-generation microRNA-based ONTs have been achieved in vitro in primary human cell cultures and in vivo in animal models. The company is developing a second generation with improved safety and pharmacokinetics. No clinical trial results yet; all programs are preclinical.

Therapeutic areas: Metabolic DisordersOncologyEndocrinologyCardiovascular
Modalities: Oligonucleotide therapeutics (ONTs)microRNA-based therapeutics (miRNA antagomirs)Peptide Nucleic Acid backbone oligonucleotides
Industry: Biotech

Drug pipeline

8 assets

lenti-miR449a

Preclinical

7 more assets in the full pipeline.

Request access →

Partnerships

Collaborations mentioned with GOG Foundation/GOG Partners/NRG Oncology and the ENGOT network of ESGO for ovarian cancer research support

Beyond the preview

Go deeper on AptamiR Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AptamiR Therapeutics.

Explore the full profile